/
ASND
$265.91-$0.81 (-0.30%)live
Held by
0
portfolios on TandT
Bookmarked by
0
users
Avg position size
—
of holders' portfolios
13F filers
0
institutions
Market cap
$17.5B
66M shares
52-week range
$160.86 – $271.89
95% from low
Exchange
NASDAQ
CS
Borrow rate
0.31%
Easy to borrow
Price (6 mo)
Loading chart…
Change+$132.07
Valuation
Financials
Loading chart…
Click rows below (any statement) to add/remove series. Selection stays as you switch tabs.
| 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $10.6M | $13.4M | $7.0M | $7.8M | $51.2M | $266.7M | $363.6M | $691.7M |
| Cost of revenue | $0 | $0 | $0 | $3.5M | $12.1M | $44.4M | $44.3M | $103.2M |
| Gross profit | $10.6M | $13.4M | $7.0M | $4.3M | $39.0M | $222.3M | $319.4M | $588.5M |
| Gross margin | 100.0% | 100.0% | 100.0% | 54.7% | 76.3% | 83.4% | 87.8% | 85.1% |
| R&D | $140.3M | $191.6M | $260.9M | $295.9M | $379.6M | $413.5M | $307.0M | $283.5M |
| Operating income | −$154.8M | −$226.7M | −$330.6M | −$451.8M | −$561.8M | −$455.5M | −$278.8M | −$130.9M |
| EBITDA | −$150.2M | −$210.4M | −$407.8M | −$364.6M | −$529.2M | −$411.2M | −$290.0M | −$109.8M |
| Net income | −$130.1M | −$218.0M | −$419.0M | −$383.6M | −$583.2M | −$481.4M | −$378.1M | −$219.0M |
| Net margin | -1229.5% | -1630.0% | -6025.5% | -4931.6% | -1139.6% | -180.5% | -104.0% | -31.7% |
| EPS (diluted) | -3.17 | -4.69 | -8.28 | -7.00 | -10.40 | -8.55 | -6.53 | -3.62 |
Annual figures · source: Financial Modeling Prep
Analyst estimates (consensus)
| Year | Est. revenue | Est. EPS | EPS range | # Analysts |
|---|---|---|---|---|
| 2026 | $1.3B | $13.36 | $12.32–$15.38 | 10 |
| 2027 | $1.9B | $9.43 | $5.67–$12.04 | 10 |
| 2028 | $2.4B | $14.40 | $7.31–$19.64 | 10 |
| 2029 | $3.0B | $17.85 | $16.30–$20.58 | 4 |
Forward consensus · source: Financial Modeling Prep
Peer comparison
Ascendis Pharma A/S Ordinary Share
Ascendis Pharma AS is a biopharmaceutical company that applies its TransCon technology platform to make a meaningful difference for patients. The firm's product pipeline includes Endocrinology and Oncology, which includes TransCon PTH, TransCon CNP, and others. It operates in the United States, Europe, and the rest of the world and derives the majority of its revenue from the United States.
www.ascendispharma.com- Employees
- 1,189
- IPO / List date
- Apr 20, 2026
Held by traders on TradeandTell
No one on the platform currently holds ASND.
Super investors & insiders
Institutions holding (13F)
No tracked institution reports a position in ASND as of their last filing.
Insider activity (SEC Form 4)
Recent trades on TradeandTell
No one on the platform has traded ASND yet.
